Risk factors
Climb Bio (CLYM) risk factors
Item 1A of every Climb Bio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors104 risks31 new42 dropped47 reworded
Climb Bio faces heightened trade tariff risks, especially on imported drug materials from China under new 2025 administration proposals. Cash reserves of $160.7 million are projected to fund operations into 2028, but heavy milestone payment obligations continue. International expansion introduces complex global privacy, tax, and regulatory hurdles.
Filed Mar 05, 2026 - FY2024 10-K risk factors115 risks
Climb Bio is a clinical-stage biotechnology company focused on developing budoprutug for immune-mediated diseases and CLYM116 for IgAN.
Filed Mar 25, 2025